The study evaluates the Czech Republic-based company’s Uris device, which uses peroneal neuromodulation (eTNM) for deep brain stimulation. The Uris system previously demonstrated high effectiveness in treating overactive bladder.
Uris, a non-invasive system, utilizes active closed-loop biofeedback. Its design aims to provide afferent stimulation of higher levels of the central nervous system through peroneal eTNM. The system stimulates the common peroneal nerve on the lower limbs of patients for home-based treatment. Uris delivers stimulation in a 30-minute session performed once daily for 12 weeks.
The study of Uris assesses the positive impact on the symptoms of patients with Parkinson’s or essential tremor disorders. Stimvia said it also evaluates the influence of the treatment on their quality of life.
According to a news release, the study includes 24 patients meeting specific criteria. Half suffer from essential tremor and half have Parkinson’s. For six weeks, patients will use Uris for 30-minute daily sessions. Following this phase, they will go six weeks without stimulation while being monitored to assess whether positive effects persist post-treatment.
Stimvia expects results from the study in the first half of 2024. It Uris provides a positive impact in the study, the company plans to invest in subsequent clinical trials.
“The electrical stimulation in the brain activates areas that are suppressed and, conversely, suppresses the activity of regions that exhibit excessive activity. The success in the pilot study for the treatment of Parkinson’s disease and essential tremor would confirm this central effect for us,” said Lukas Doskocil, CEO of Stimvia.
